Longevity Focus The Longevity Fund (age1) is a pioneer in longevity biotech investing, with a portfolio that has raised over $1B and driven multiple programs to the clinic, signaling ongoing growth potential for founders and limited partners in the age-related disease space.

Active Investments Recent moves include a $100M Series C investment into Loyal for potential lifespan-extending therapies and a $21M seed round into Aerska for RNAi-based neurological disease programs, indicating active deal sourcing and startup momentum.

Platform Evolution Age1 represents the next generation of longevity investing as the successor to The Longevity Fund, suggesting opportunities to engage with a refreshed mandate, new syndication angles, and expanded co-investment possibilities.

Early-Stage Advantage Financing activity in early stages (seed to Series C) combined with notable fund traction implies potential collaboration on due diligence services, portfolio support platforms, and value-add partnerships for portfolio companies.

Strategic Fit With roots in longevity and aging research, there is potential alignment with service providers in biotech regulatory strategy, clinical development, animal health for lifespan extension, and data analytics for clinical endpoints appealing to age1 and its portfolio.